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A COVID-19 vaccine has been positioned by governments since the beginning as the way to 
control the pandemic and return normal social and economic functioning. As a result, the 
news in November 2020 that an effective COVID-19 vaccine might be available for use by 
healthcare professionals and in certain vulnerable populations before the end of the year (and 
more widely in 2021) has caused great excitement (1). This said, scientific questions remain 
about lasting immunity created by COVID-19 vaccination and efficacy in older people (2). 
There are also a vast range of manufacturing and distribution issues to be navigated in 
vaccinating billions of people globally. Importantly, the science of vaccine research and 
development cannot end the pandemic alone. When the efficacy and safety of a COVID-19 
vaccine or vaccines can be established, social factors will play a highly significant role in the 
success of vaccines in controlling the COVID-19 pandemic. 
 One of the key questions that sociologists can contribute to answering is whether 
people will accept COVID-19 vaccination and the associated question of whether the numbers 
will be high enough to achieve herd immunity (thus limiting the continued spread of the 
disease and protecting vulnerable people). Some initial research suggests this will vary 
significantly across cultural and political contexts and research in the US setting indicates 
that as many as one-fifth of Americans are displaying COVID-19 vaccine hesitancy and may 
be unwilling to receive a COVID-19 vaccine. Why might this be? What social factors shape 
vaccine hesitancy or outright rejection? In this vein, it is the purpose of this article to review 
and assert the utility of sociological knowledge about vaccines. Building on our previous work, 
we also want to pose a range of, as yet, unanswered questions about COVID-19 vaccination 
and thus offer an agenda for sociological research. Alongside exploring the social influences 
on vaccine hesitancy, we also argue that to effectively control the COVID-19 pandemic 
sociological analysis is also required of the processes of development and regulation of 
COVID-19 vaccines and of inequalities in the access to and availability of vaccines.  
 
Social Influences on Vaccine Attitudes  
The World Health Organisation (WHO) recommends that 95% of all children are vaccinated 
against vaccine preventable diseases. However, in 2018/2019 the UK fell short of  this target 
for every routine childhood vaccine. This said, vaccine refusal rates only tell some of the story, 
as can a focus solely on anti-vaxxers. Hesitancy about vaccines is more widespread (including 
people who hold doubts about safety and necessity yet may have consented to vaccines). 
Vaccine hesitancy is important to understand because it has the potential to turn into 
outright vaccine refusal in the future amongst wider numbers of people. Though critical 
attitudes towards vaccines are nothing new (3), sociologists and anthropologists have 
accumulated a large body of research concerned with the social basis of contemporary 
vaccine hesitancy and refusal.  
What does this research reveal? Safety is the major concern for those displaying 
vaccine hesitancy. However, as we argue elsewhere, vaccine hesitancy reflects a number of 
aspects including perceptions of risk and social responsibility, and past experiences with 
vaccines, pharmaceuticals, and experiences and interactions within healthcare settings more 
generally. Contemporary vaccine hesitancy and outright anti-vaccination sentiment are also 
influenced by various forms of news media, the internet, and certainly social media. Most 
importantly, future willingness to accept COVID-19 vaccination will also reflect levels of 
(dis)trust in medical professionals, healthcare and government authorities, and the 
pharmaceutical industry. Sociologists have argued that one strategy for building and 
sustaining trust at the institutional level is through policies which enhance transparency and 
accountability by making the public aware of uncertainties and risks rather than masking 
them.     
Whilst this body of knowledge allows us to predict why people might be hesitant 
towards a COVID-19 vaccine, a large proportion of the research on attitudes towards vaccines 
is concerned with parental decision-making. It is not necessarily clear if and how parental 
attitudes about vaccination are reflected more generally. It is also unclear how the special 
circumstances of COVID-19, namely the vast social and economic disruption it has caused, 
might shape public willingness to accept COVID-19 vaccination compared with other diseases 
where health, social and economic threats are less immediately obvious (at least at this point 
in time). In a possible context where COVID-19 vaccination is required multiple times to 
develop or sustain immunity, these questions are perhaps particularly important.  
 
Vaccine Development and Regulation 
To what extent can vaccine manufacturers be relied on to develop vaccines that position 
global public health as the primary interest? At a general level, there has been concern that 
guidance on minimum standards for a COVID-19 vaccine produced by the WHO (including 
50% efficacy levels (4) and comparison between vaccines rather than solely against placebo) 
might be ignored in the haste for a vaccine. Equally, though some companies have received 
public money and promised not to profit from COVID-19 vaccine development, at least at this 
stage, others have invested their own money into vaccine development and are treating it as 
a commercial opportunity. The combination of the rush to develop a vaccine alongside the 
lure of billions in potential profits could result in a suboptimal vaccine creating only short 
lived immunity and/or the curtailment of ongoing trials of potentially better vaccines. 
 There are also questions about the relationships between pharmaceutical and 
biotechnology companies, regulators and governments. To what extent does COVID-19 
represent a unique regulatory situation? In this regard, regulators have launched rolling 
reviews of vaccine data to attempt to shorten approval times. More generally, is the 
regulatory apparatus sufficiently independent to ensure the safety, efficacy and quality of 
vaccines? Sociologists have long shown how relationships between the regulatory state and 
pharmaceutical companies have biased science away from the public interest. The regulation 
of pharmaceuticals has, in this regard, been argued to be underpinned by neoliberal 
corporate bias where companies have established privileged influence within regulatory 
procedures. Sociological research is required to assess the extent to which corporate bias 
might be present in COVID-19 vaccine regulation, to chart the specific impacts and influences 
of commercial (and political) interests, and to assess the associated extent to which global 
regulatory standards are upheld. Sociological research can also reveal the range of the forms 
of uncertainty that exist in regulation as well as how they are managed.   
Governments and various forms of media have throughout the pandemic placed and 
fostered great hope that a safe and effective vaccine can and will be developed - that vaccine 
science can ultimately prevail to preserve life and restore normal social and economic 
functioning. In this regard, there are questions to be asked in the sociologies of hope and 
expectations about how these phenomena are reflected in or have structured responses to 
the COVID-19 pandemic. In this regard, the role of hope in the ability to attract vast levels of 
funding and government willingness to share the financial risks of vaccine development with 
pharmaceutical/biotechnology companies should be explored.  
Trust and hope are means of bridging uncertainty, but specific uncertainties that are 
perhaps less well mediated by trust and hope exist in relation to the implications of a ‘hard’ 
Brexit (with the transition period ending on 1st January 2021). Brexit could have a damaging 
effect on supply chains and result in long delays in accessing vaccines manufactured on the 
continent. The impacts of Brexit will need to be considered as part of broader analyses of all 
the moving parts of the pandemic and attempts to manufacture and distribute vaccines.  
 
Vaccination Programmes: Access and Availability  
Assuming the availability of a safe and effective vaccination, there will be need for sociological 
analysis and policy evaluation of vaccination programmes. How might national and 
international inequalities shape availability and access to vaccines? The whole world is going 
to require access to a vaccine. But there has been concern that vaccine nationalism, where 
governments sign agreements with vaccine manufacturers to supply their own populations 
first, might mean that poorer countries have to wait or cannot afford a vaccine. The COVID-
19 Global Access (COVAX) initiative, co-led by the WHO, is seen by some as the solution to 
the problem of vaccine nationalism. It has been signed by 172 countries to create a global 
advanced market commitment for vaccines which will ostensibly protect low-and middle-
income countries. However, the US (under President Trump) has opted out and, when 
supplies are divided up between countries doses could be insufficient. There are a range of 
vaccines that have received investment via COVAX, but it unclear how easy it will be to 
ethically and political navigate the distribution to different countries of vaccines that 
potentially show different levels of efficacy. Equally, signing up to COVAX does not prevent 
rich countries from striking their own deals (which could create pressures in the supply chain 
and drive prices up). The damages of the COVID-19 pandemic have not been felt by all 
countries equally, and neither, it seems, will the benefits of vaccines. These issues will require 
empirical investigation.  
 There are also important comparative questions to be asked about how public and 
private healthcare systems provide access to vaccines and how existing inequalities within 
countries shape who or how quickly someone can be vaccinated. Equally, there are ethical 
questions requiring exploration about the order in which people might receive vaccines. 
Healthcare professionals and the elderly are first in line for a vaccine. However, in the UK, 
COVID-19 has exacerbated existing inequalities. There have been disproportionate impacts 
regionally, on ethnic minorities, and on the poor which have not been reflected in initial 
vaccine prioritisation order.  
 
Notes:  
1) Pfizer (in partnership with BioNTech) were the first to announce that they had 
developed an effective vaccine and were very close to having compiled enough 
efficacy and safety data to seek regulatory approval for their vaccine (and is now under 
review in the US), followed by biotechnology company Moderna. Many more are in 
the preclinical or clinical trial phases of development.  
2) Early evidence suggests that COVID-19 vaccines have produced strong immune 
responses in older people. 
3) See Calnan and Douglass, 2020 for a discussion of the history of vaccination and the 
persistence of vaccine critical attitudes.  
4) Pfizer and Moderna have both claimed their vaccines have over 90% efficacy - but this 
needs to be verified by regulators.    
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